What is the current stock price of Legend Biotech Corporation (LEGN)?

As of the latest market data, Legend Biotech Corporation (LEGN) is trading at $28.50. The stock has seen a loss of -3.49% today.

Does Legend Biotech Corporation (LEGN) pay a dividend?

Based on current data, Legend Biotech Corporation does not have a confirmed active dividend policy.

What is the market cap of Legend Biotech Corporation?

The current market capitalization of Legend Biotech Corporation (LEGN) is approximately unavailable.

LEGN

Legend Biotech Corporation·Healthcare

28.50

3.488%(−1.03)

Close Price

29.00

1.754%(+0.50)

Pre-Market

Last Updated: — ET

52W L: $16.2452W H: $45.30

LEGN NEWS

globenewswire.com

6d ago

Legend Biotech Announces Presentations at ASCO 2026

SOMERSET, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech or the Company), a global leader in cell therapy, today announced multiple presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, including a rapid oral presentation highlighting preliminary Phase 1 data for LB2102, its investigational DLL3-targeted CAR-T therapy for relapsed or refractory small-cell lung cancer (SCLC) and large-cell neuroendocrine carcinoma (LCNEC).

fool.com

May 17

A China Tech Fund Opens a Biotech Position — Here's What That Actually Signals

Legend Biotech develops cell therapies for cancer, with a pipeline spanning hematologic malignancies and solid tumors.

247wallst.com

May 14

Big Pharma's 5 Hottest Biotech Hunting Grounds: Meet the Category Leaders

Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers face looming patent cliffs and hunt for growth.

benzinga.com

May 13

These Analysts Revise Their Forecasts On Legend Biotech After Q1 Results

Legend Biotech Corp (NASDAQ:LEGN) reported downbeat results for the first quarter on Tuesday.

seekingalpha.com

May 12

Legend Biotech Corporation (LEGN) Q1 2026 Earnings Call Transcript

marketbeat.com

May 12

Legend Biotech Q1 Earnings Call Highlights

Legend Biotech NASDAQ: LEGN reported sharply higher first-quarter 2026 sales for CARVYKTI, its CAR T therapy for multiple myeloma, as management said demand continued to move into earlier lines of treatment and international markets expanded.

Company Profile

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Sector

Healthcare

Industry

Biotechnology

Employees

2,600

IPO Date

2020-06-05

Beta

0.30

Websitewww.legendbiotech.com↗